PRN: 'Ophthalmic Drugs Market Will Reach $18.7 Billion in 2012' Visiongain Report Predicts

21/mar/2012 12:53:21 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

'Ophthalmic Drugs Market Will Reach $18.7 Billion in 2012' Visiongain Report Predicts


LONDON, March 21, 2012 /PRNewswire/ --

A new report by visiongain predicts that the world market for ophthalmic drugs will reach $18.7 billion for 2012. That revenue forecast appears in Ophthalmic Drugs: World Market Prospects 2012-2022, published in March 2012. Visiongain is a business information provider based in London, UK.

From 2012 to 2022, the pharmaceutical industry will improve treatment of ocular disorders and increase revenues from those products. The R&D pipeline for treating eye diseases is strong. Visiongain's study predicts that the world market for eye drugs will grow strongly from 2012 to 2022. It will be stimulated by increasing prevalence of eye disorders among aging populations worldwide. Sustained-release ocular implants, gene therapy and RNA interference technology will influence R&D in ophthalmology, as will neuroprotective agents for glaucoma. Many commercial opportunities for ophthalmic drugs exist, with high revenues possible this decade.

Dr Syed Ahmed, a senior pharmaceutical industry analyst at visiongain, said, "The world market for ophthalmic drugs is an important segment of the pharma industry. The main causes of visual impairment and sight loss in developed countries are retinal diseases. These include age-related macular degeneration (AMD), diabetic macular oedema and macular oedema caused by retinal vein occlusion. Glaucoma is the leading cause of irreversible blindness. It remains a large segment of the ophthalmic prescription drug market. Worldwide, there are many under-met treatment needs for eye disorders.

"Over coming years, there will be much research in ophthalmics, especially for sustained release implants and injection technologies for retinal diseases. Improved drug delivery and new formulations will be important. Sustained release formulations will offer marked potential for revenue growth. Diabetic macular oedema (DME) will also be important to the future of the ophthalmic drug market. The number of people developing Type II diabetes is rising, with many diabetics developing DME. In particular, anti-VEGF therapy will play an increasing role in the treatment of DME."  

Visiongain's report provides revenue forecasts to 2022 at world market, therapeutic submarket, product and national level. It forecasts world sales for the following submarkets:

- Glaucoma treatments

- Anti-allergy, anti-inflammatory and anti-infective agents

- Retinal disorder treatments

- Dry eye treatments

- Other medicines.

That investigation forecasts sales of 20 leading drugs, including Lucentis, Visudyne, Xalatan/Xalacom and Restasis. Research, data and analyses cover activities of Allergan, Novartis, Pfizer, Roche and other pharmaceutical companies.

The analysis includes researching the R&D pipeline, interviewing authorities on the industry and forecasting revenues in leading national markets. Countries analysed are the US, Japan, the EU5, Brazil, China and India. Ophthalmic Drugs: World Market Prospects 2012-2022 adds to visiongain's range of analytical reports on industries and markets in healthcare.

For sample pages and further information concerning the Visiongain report Ophthalmic Drugs: World Market Prospects 2012-2022 please visit:

For an executive summary and to order this report please contact:
Email: Sara Peerun on

Tel: +44(0)20-7336-6100

Companies Listed

Alcon (Novartis)
Alimera Sciences
American Academy of Ophthalmology (AAO) [US]
American Society of Retina Specialists (ASRS) [US]
Asahi Glass
Association for Research in Vision and Ophthalmology
Bausch & Lomb
Bristol-Myers Squibb
Can-Fite BioPharma
Cerimon Pharmaceuticals
Chugai Pharmaceutical Corp.
Daiichi Sankyo
Danube Pharmaceuticals
Eli Lilly
European Medicines Agency (EMEA/EMA)
EyeGate Pharmaceuticals
Eyetech Pharmaceuticals
Food and Drug Administration (FDA) [US]
Fovea Pharmaceuticals
Galderma International SA (Nestlé and L'Oréal)
InSite Vision
Inspire Pharmaceuticals
ISTA Pharmaceuticals
Johnson & Johnson
Kowa Company
Kyorin Pharmaceutical Co.
Kyowa Hakko Kirin Corp.
Laboratorios Sophia
LEO Pharma
Lux Biosciences
Meda Pharmaceuticals
Merck & Co.
Ministry of Health, Labour and Welfare [Japan]
Moorfields Eye Hospital [UK]
National Eye Institute (NEI) [US]
National Health Service (NHS) [UK]
National Institute for Health and Clinical Excellence (NICE) [UK]
National Institutes of Health (NIH) [US]
NovaBay Pharmaceuticals
OPKO Health
OSI Pharmaceuticals
Othera Pharmaceuticals
Otsuka Pharmaceutical Corp.
Oxford Eye Hospital [UK]
Paladin Labs
Quark Pharmaceuticals
Ranbaxy Laboratories
Regeneron Pharmaceuticals
ReVision Therapeutics
Rutgers University, Springfield, New Jersey [US]
Santen Pharmaceutical Corp.
Sanwa Kagaku Kenkyusho Corp.
SARcode Corporation
Senju Pharmaceuticals
Shire Pharmaceuticals
Sirion Therapeutics
Sirna Therapeutics
SKS Ocular
Sunesis Pharmaceuticals
Symphony ViDA
Takeda Pharmaceuticals
Targeted Genetics
Teva Pharmaceutical Industries
University College of London (UCL), Institute of Ophthalmology [UK]
University of Aston, Birmingham [UK]
University of Oxford [UK]
Watson Pharmaceuticals 

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. 

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to or call her on +44(0)207-336-6100

blog comments powered by Disqus è un servizio offerto da Factotum Srl